NovaBridge Biosciences (NBP) Cash & Current Investments (2018 - 2025)

NovaBridge Biosciences (NBP) has 8 years of Cash & Current Investments data on file, last reported at $210.8 million in Q4 2025.

• Quarterly Cash & Current Investments rose 21.59% year-over-year to $210.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $210.8 million (up 21.59% YoY) and the FY2025 annual result came in at $210.8 million, up 21.59% from the prior year.
• Cash & Current Investments fell to $210.8 million in Q4 2025 per NBP's latest filing, from $228.3 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $118.4 billion in Q4 2021 and bottomed at $165.6 million in Q2 2025.
• The 5-year median for Cash & Current Investments is $317.3 million (2023), against an average of $9.4 billion.
• The widest annual swing landed in 2021, when Cash & Current Investments soared 16273.69%; it then tumbled 99.61% in 2022.
• Tracing NBP's Cash & Current Investments over 5 years: stood at $118.4 billion in 2021, then plunged by 99.61% to $465.5 million in 2022, then sank by 31.84% to $317.3 million in 2023, then sank by 45.35% to $173.4 million in 2024, then increased by 21.59% to $210.8 million in 2025.
• Per Business Quant, the three latest NBP Cash & Current Investments figures stand at $210.8 million (Q4 2025), $228.3 million (Q3 2025), and $165.6 million (Q2 2025).

Peer Comparison